Paris Abstracts

PRS13
THE CZECH BURDEN STUDY: SUBGROUP ANALYSIS (BURDEN AND QUALITY OF LIFE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATION) Shafkat M, Kulikov A1, Demko IV2, Tolkushin A3, Ogorodova LM4, Chuchalin AG5, Yagudina RI1, Kulikov A1, Demko IV2, Tolkushin A3, Ogorodova LM4, Chuchalin AG5

To compare maintenance (using the fixed combination of Salmeterol + Fluticasone vs. SAL/FP) and symptomatic (no maintenance) treatment of asthma with a developed transparent pharmacoeconomic model. METHODS: Lack of asthma control leads to unscheduled resources utilization and so growth of total cost (direct and indirect). Algorithm of OPTIMA model calculation includes 4 steps: 1) Analysis of weighted average cost of maintenance medicines based on dosing, average prices in reimbursement, and dose distribution in assessing population, and 2) Assessment of cost associated with controlled and uncontrolled asthma based on number of unscheduled resources utilization (unscheduled service, outpatient visits, laboratory tests, and work-off days) and their unit-cost (sources-current Russian legislation, Rosstat data) as well as QoL, 3) Detection of frequency of controlled/uncontrolled asthma in terms of clinical trials data, 4) Calculation of total cost in asthma (cost of drug + % controlled + cost of controlled + % uncontrolled + cost of uncontrolled) and amount of saving. RESULTS: Weighted average cost of SAL/FP in Russia was 1672 Rub (~40 EUR) per month. Cost associated with controlled and uncontrolled asthma were 320 Rub and 62,753 Rub (~48 and 1,400) per patient per year, respectively. QoL scores were 0.75 and 0.69 respectively. Frequency of controlled asthma in the study arm was 75% (GOAL study) and so 25% patients were uncontrolled. Assumed frequency of controlled asthma using symptomatic treatment instead of SAL/FP was ~5%. Total costs were 35,991 Rub and 59,632 Rub (~850 and 1,400) in maintenance and symptomatic arms, respectively; average QoL score was 0.69 and 0.53 respectively. CONCLUSIONS: The model allows transparent comparisons of different asthma treatment approaches. Maintenance treatment with SAL/FP was superior (less cost and higher QoL) to symptomatic treatment.

PRS14
MEDICAL AND PRODUCTIVITY COSTS ATTRIBUTABLE TO OBESITY IN WORKING ADULTS WITH ASTHMA IN THE U.S. Sub DC, Kim CM1, Kwon JW1, Choi IS1, Yang JH1, Barone JA1

The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from government sources. The participants of each group experienced different transition probabilities based on their age and disease-specific morbidity and mortality rates. Vital statistics, disease-specific morbidity and mortality rates were obtained from governme...